New hope for patients with rare, aggressive blood cancer

NCT ID NCT06043674

First seen Jan 08, 2026 · Last updated Apr 16, 2026 · Updated 13 times

Summary

This study is testing whether a drug called glofitamab, either by itself or combined with other medications, can help people with Richter's Transformation. This is a serious condition where a slower blood cancer (CLL) turns into a fast-growing lymphoma. About 70 adults will receive treatment for about 9 months and be followed for up to 10 years to see how well the treatments work and how safe they are.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Email: •••••@•••••

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Email: •••••@•••••

  • The Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

  • The University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Email: •••••@•••••

    Contact

  • Winship Cancer Institute at Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.